Multimodal Cardiovascular and Hepatic Population Imaging
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Imaging examinations, Paramedical examinations, Medical examination, Echocardiography.
- Who it may be relevant to
- Registry conditions: Healthy Volunteers, Imaging Evaluation. Basic parameters: from 20 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Medical imaging is increasingly important for understanding diseases, detecting them early, and personalizing treatments. New imaging techniques, which can measure processes in the body without surgery, are opening the door to a more precise approach to medicine. Instead of relying on general probabilities, this technology allows us to analyze specific factors in a person's health, leading to better predictions and targeted treatments. One key challenge in medicine today is reducing "residual individual risk"-the remaining health risks that current treatments don't fully address. This involves understanding how factors like age, sex, genetics, and environment affect our health, particularly when it comes to conditions like heart and liver disease. By using imaging to distinguish between normal aging and disease, we can better assess individual health risks. The current project will create a large collection of medical images linked with health data from a broad population across France. Using advanced, non-invasive techniques such as MRI and ultrasound, researchers will analyze the heart, blood vessels, and liver in detail, considering factors like gender and health risk profiles. This will help improve our understanding of these diseases, which are often silent and not well understood, providing direct benefits to the participants. Ultimately, the goal is to optimize imaging technologies for large-scale studies, which will help enhance early detection and prevention for everyone.
Interventions
- Radiation Imaging examinations
* Cardiovascular MRI * Hepatic MRI * Hepatic ultrasound - Other Paramedical examinations
* Urinary pregnancy test for women of childbearing age. * Blood sample for cardiometabolism profiling * Blood samples for biobanking (according to the information and consent form) * Impedancemetry * AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device. - Other Medical examination
* Review of risk factors * Review of previous history * Recording of current medication (dci, dose, start date) * Recording of medication in the last 6 months and discontinued since (dci, dose, start date) - Other Echocardiography
Echocardiography including: 12-lead digital ECG
Primary outcome measures
- Establishement of reference nomograms accounting for age in heart [Time frame: During 36 months of analysis (after 60 months of inclusion)]
- Establishement of reference nomograms accounting for sex in heart [Time frame: During 36 months of analysis (after 60 months of inclusion)]
- Establishement of reference nomograms accounting for age in liver [Time frame: During 36 months of analysis (after 60 months of inclusion)]
- Establishement of reference nomograms accounting for sex in liver [Time frame: During 36 months of analysis (after 60 months of inclusion)]
- Establishement of reference nomograms accounting for age in adipose tissue [Time frame: During 36 months of analysis (after 60 months of inclusion)]
- Establishement of reference nomograms accounting for sex in adipose tissue [Time frame: During 36 months of analysis (after 60 months of inclusion)]
Secondary outcome measures (4)
- Advanced Imaging profiling of Heart [Time frame: During 36 months of analysis (after 60 months of inclusion)]
- Advanced imaging profiling in Liver [Time frame: During 36 months of analysis (after 60 months of inclusion)]
- Advanced biological phenotyping [Time frame: During 36 months of analysis (after 60 months of inclusion)]
- identification of genetic risk markers for cardio-metabolic diseases [Time frame: During 36 months of analysis (after 60 months of inclusion)]
Eligibility criteria
Inclusion criteria
- Participation to the Constances cohort
- Age ≥ 20 years
- No overt cardiovascular or hepatic disease or related symptoms
- No known family or personal genetic disease
- Affiliation with a social security scheme or beneficiary of such a scheme.
- Agreement to sign the consent
Exclusion criteria
- Renal function impairment with GFR < 60 mL/min/1.73m2
- Deprived of liberty or persons subject to a legal protection measure (under guardianship or trusteeship)
- People with contraindications to MRI (claustrophobia, presence of metallic elements…)
- Pregnant or breastfeeding woman (pregnancy urinary test before inclusion for women of childbearing age).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Hôpital Pitié-Salpêtrière — Paris
Publications
- Mauger CA, Gilbert K, Suinesiaputra A, Bluemke DA, Wu CO, Lima JAC, Young AA, Ambale-Venkatesh B. Multi-Ethnic Study of Atherosclerosis: Relationship between Left Ventricular Shape at Cardiac MRI and 10-year Outcomes. Radiology. 2023 Feb;306(2):e220122. doi: 10.1148/radiol.220122. Epub 2022 Sep 20. PMID 36125376
- Bohnen S, Avanesov M, Jagodzinski A, Schnabel RB, Zeller T, Karakas M, Schneider J, Tahir E, Cavus E, Spink C, Radunski UK, Ojeda F, Adam G, Blankenberg S, Lund GK, Muellerleile K. Cardiovascular magnetic resonance imaging in the prospective, population-based, Hamburg City Health cohort study: objectives and design. J Cardiovasc Magn Reson. 2018 Sep 24;20(1):68. doi: 10.1186/s12968-018-0490-7. PMID 30244673
- Nie C, Li Y, Li R, Yan Y, Zhang D, Li T, Li Z, Sun Y, Zhen H, Ding J, Wan Z, Gong J, Shi Y, Huang Z, Wu Y, Cai K, Zong Y, Wang Z, Wang R, Jian M, Jin X, Wang J, Yang H, Han JJ, Zhang X, Franceschi C, Kennedy BK, Xu X. Distinct biological ages of organs and systems identified from a multi-omics study. Cell Rep. 2022 Mar 8;38(10):110459. doi: 10.1016/j.celrep.2022.110459. PMID 35263580
- Laurent S, Boutouyrie P, Cunha PG, Lacolley P, Nilsson PM. Concept of Extremes in Vascular Aging. Hypertension. 2019 Aug;74(2):218-228. doi: 10.1161/HYPERTENSIONAHA.119.12655. Epub 2019 Jun 17. No abstract available. PMID 31203728
Identifiers
NCT: NCT06906042 · C24-17 · 2024-A02188-39